| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Total revenues | $222K+441.5% | $41K-94.2% | $709K-24.6% | $940K-28.0% | $1.3M-76.8% | $5.6M |
| Cost of revenues | $396K-22.0% | $508K+4.1% | $488K-32.7% | $725K+1.3% | $716K-81.2% | $3.8M |
| Gross profit | $803K-57.4% | $1.9M+752.5% | $221K-55.5% | $497K-15.8% | $590K-67.7% | $1.8M |
| General and administrative | $12.0M+17.3% | $10.3M-15.7% | $12.2M+50.1% | $8.1M-16.6% | $9.7M+256.6% | $2.7M |
| Research and development | $12.0M+48.0% | $8.1M-10.2% | $9.1M-3.2% | $9.4M+32.1% | $7.1M+165.2% | $2.7M |
| Total operating expenses | $24.1M+30.9% | $18.4M-13.4% | $21.3M+14.6% | $18.5M+2.7% | $18.0M+222.0% | $5.6M |
| Loss from operations | -$23.3M-40.9% | -$16.5M+21.4% | -$21.0M-16.5% | -$18.0M-3.4% | -$17.5M-362.0% | -$3.8M |
| Loss on disposal of assets | -$97K | — | — | — | — | — |
| Other income (expense), net | $680K+23.9% | $549K+245.6% | -$377K-225.7% | $300K-27.0% | $411K+621.1% | $57K |
| Total other income (expenses), net | $583K+6.2% | $549K+243.0% | -$384K+51.5% | -$792K | — | — |
| Net loss | -$22.7M-42.1% | -$16.0M+25.4% | -$21.4M-13.7% | -$18.8M-10.5% | -$17.0M-358.1% | -$3.7M |
| Deemed dividend - warrant inducement offers | $0+100.0% | -$8.7M-984.0% | -$798K | — | — | — |
| Net loss attributable to common stockholders | -$22.7M+7.8% | -$24.6M-10.9% | -$22.2M-17.9% | -$18.8M | — | — |
| Basic net loss per share | -$1290.00+50.8% | -$2620.00+74.4% | -$10220.00-1035.6% | -$900.00-99900.0% | -$0.90 | — |
| Diluted net loss per share | -$1290.00+50.8% | -$2620.00+74.4% | -$10220.00 | — | — | — |
| Basic weighted average common shares outstanding | 17.58B+86.8% | 9.41B+333.0% | 2.17B-89.6% | 20.97B+10.9% | 18.92B | — |
| Diluted weighted average common shares outstanding | 17.58B+86.8% | 9.41B+333.0% | 2.17B | — | — | — |
| Clinical trial revenue | ||||||
| Contract manufacturing lease revenue | ||||||
| Contract manufacturing revenue | ||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.